With partners all over the world
Denmark
Headquarter
In the north of Copenhagen
Sweden
England
Spain
Germany
Poland
India
United States
Canada
The whole world is our workplace
Based in Denmark, Orocidin is developing a proprietary first-of-its kind medical treatment (QR-01) designed to treat aggressive periodontitis and improve patients’ oral health – addressing a major unmet need.
- Today’s treatments are inadequate with limited efficacy.
- No existing treatment combines both antibacterial and anti-inflammatory properties, which are crucial for effectively combating periodontitis.
Several patent applications have already been submitted, including product use, application forms, and synthesis.
Headquartered north of Copenhagen, our core team leads the company’s strategic, commercial, and administrative functions.
We work closely with a global network of specialized partners – including development and manufacturing organizations, as well as scientific and legal advisors – to advance our drug development program efficiently.
Visions and goals
Orocidin was established by Allan Wehnert whose vision has always been to study and develop novel innovative drugs for diseases for which there is no current treatment options or to improve inadequate current treatments.
Orocidin and periodontitis represent such an opportunity, and where Allan discovered a novel method to solve the problem of the lack of treatment. Until now, all treatments under investigation have focused on the bacterial infection and not the fact that periodontitis is an inflammatory disorder causing the teeth to degrade and worsening the adhesion to gum tissue.
So, a treatment with both antimicrobial and anti-inflammatory properties is an ideal way to treat periodontitis – highlighting Orocidin’s potential.
In 2024, Orocidin became a wholly owned subsidiary of the publicly traded U.S. life sciences business accelerator and holding company, Nordicus Partners Corporation (OTCQB: NORD).
Management
Allan Wehnert
CEO & Founder
Allan Wehnert brings more than three decades of experience in the pharmaceutical sector, with a focus on the discovery and development of new molecules for central nervous system disorders. As a trained pharmacologist, he has published 25 scientific papers in leading international journals. In his previous role as Senior Vice President for Research and Development at Initiator Pharma, he advised private equity syndicates. Furthermore, Allan is also the owner of Decision Insights.
Allan worked at Lundbeck A/S for 25 years, during which he served as Senior Vice President and was responsible for advancing drug candidates from preclinical phases through to NDA and EMA approval. Allan led drug development of 8 new chemical entities to FDA and EMA. In addition, Allan has performed more than 200 due diligence evaluations and has played a key role in license and acquisition deals.
Board of Directors
Peter Severin
Chairman
Peter Severin brings over 25 years life sciences and sales experience to Orocidins Board.
Peter Severin is currently the Founder and CEO of Severin Partners, a sales and communications consulting company focusing on the healthcare industries.
Peter Severin also serves as Chairman of the U.S.- based Life Sciences holding company, Nordicus Partners Corporation. Prior to founding Severin Partners, Peter held positions as Head of Sales of Novartis AG, Sales Manager at AstraZeneca Pharmaceuticals and as Sales Manager of GSK Plc (formerly GlaxoSmithKline Plc).
Henrik Rouf
Member
Henrik Rouf has 30 years of experience in the global finance markets, working as an international financier, merchant banker and fund manager, respectively. Henrik Rouf advises and finances companies in many industries, including (though not limited to) software, semiconductors, blockchain, healthcare, medical devices, biotechnology, restaurant chains, apparel, cannabis, clean tech and advertising.
Henrik Rouf has since 2004 been the President of PacificWave Partners Inc., a California-based merchant bank, and is also currently the CEO of the U.S. based Life Sciences holding company, Nordicus Partners Corporation. By being located and working in the United States for more than 30 years, Mr. Rouf has a vast network and extensive ties to especially the U.S., but also to Europe and Asia.
Christian Hill-Madsen
Member
Christian Hill-Madsen has over 25 years of experience in the Life Sciences industry, including serving as a headhunter. He possesses an extensive network and unique knowledge within the Life Sciences/Biotech sector, and has proven experience in identifying top talent, build strong teams, and improve organizational structures. This expertise in talent acquisition and workforce dynamics plays a key role in ensuring the companies he is involved with is well-positioned with the right people to support its growth and innovation.